ArticleBMC pulmonary medicine2019
Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.
Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Ventilatory inefficiency limits 6-min walked distance in systemic sclerosis-associated interstitial lung disease.Scientific reports · 2025Article
- How to Assess Pulmonary Circulation and Right Heart Chambers in Systemic Sclerosis Patients?Diagnostics (Basel, Switzerland) · 2025Review
- Cardiac Involvement and Heart Failure Staging in Patients with Systemic Sclerosis Without Pulmonary Arterial Hypertension.Journal of clinical medicine · 2025Article
- Exercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing.Journal of clinical medicine · 2025Review
- Chest wall muscle area, ventilatory efficiency and exercise capacity in systemic sclerosis.Internal and emergency medicine · 2025Article
- Cardiopulmonary Exercise Testing: Deciphering Cardiovascular Complications in Systemic Sclerosis.Reviews in cardiovascular medicine · 2025Review
- Risk stratification and treatment goals in pulmonary arterial hypertension.The European respiratory journal · 2024Review
- A Summed Score From Cardiopulmonary Exercise Test Parameters Predicts 1-Year Mortality in Newly Diagnosed Interstitial Lung Disease.Respiratory care · 2024Article
- Metabolic cost of unloading pedalling in different groups of patients with pulmonary hypertension and volunteers.Scientific reports · 2024Article
- Unmasking a Silent Threat: Improving Pulmonary Hypertension Screening Methods for Interstitial Lung Disease Patients.Medicina (Kaunas, Lithuania) · 2023Review
- In systemic sclerosis TAPSE/sPAP ratio is correlated with ventilatory efficiency and exercise capacity assessed by CPET.Clinical and experimental medicine · 2023Article
- Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.Clinical rheumatology · 2023Review
- Right Ventricular Morphology and Function after Exercise Training in People with Systemic Sclerosis: A Randomized Controlled Pilot Study.Life (Basel, Switzerland) · 2023Article
- Systemic sclerosis associated interstitial lung disease: a survey of current practices in France.Therapeutic advances in musculoskeletal disease · 2023Article
- Assessment of disease outcome measures in systemic sclerosis.Nature reviews. Rheumatology · 2022Review
- Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study.Rheumatology international · 2022Observational
- Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality.Arthritis research & therapy · 2021Observational
- Ventilatory efficiency in pulmonary vascular diseases.European respiratory review : an official journal of the European Respiratory Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic sclerosis (SSc) is a severe rheumatic disease of the interstitial tissue, in which heart and lung involvement can lead to disease-specific mortality. Our study tests the hypothesis that in addition to established prognostic factors, cardiopulmonary exercise testing (CPET) parameters, particularly peak oxygen uptake (peakVO SUBJECTS AND
methodsWe retrospectively assessed 210 patients (80.9% female) in 6 centres over 10 years with pulmonary testing and CPET. Survival was analysed with Cox regression analysis (adjusted for age and gender) by age, comorbidity (Charlson-Index), body weight, body-mass index, extensive interstitial lung disease, pulmonary artery pressure (measured by echocardiography and invasively), and haemodynamic, pulmonary and CPET parameters.
resultsFive- and ten-year survival of SSc patients was 93.8 and 86.9%, respectively. There was no difference in survival between patients with diffuse (dcSSc) and limited cutaneous manifestation (lcSSc; p = 0.3). Pulmonary and CPET parameters were significantly impaired. Prognosis was worst for patients with pulmonary hypertension (p = 0.007), 6-min walking distance < 413 m (p = 0.003), peakVO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.